Successful Treatment of Chronic Spontaneous Urticaria Associated with Autoimmune Thyroiditis: Clinical Case
Vera G. Kalugina,
Leyla S. Namazova-Baranova,
Elena A. Vishnyova,
Anna A. Alexeyeva,
Yliya Levina,
Polina S. Arimova https://doi.org/10.15690/pf.v16i4.2052
Abstract
Chronic spontaneous urticaria (CSU) can be associated with some autoimmune diseases which may affect the CSU course. Autoimmune thyroiditis can cause severe CSC. 2nd generation antihistamines are the golden standard of CSY therapy. However, even dose-escalation in some cases will not lead significant improvement. Nowadays there are not enough studies about other medications administration in children with CSU. Omalizumab is the only genetically engineered biologic drug for treatment of resistant (to standard therapy) forms of CSU, it can be used in children over 12 years old. We would like to present our data on one adolescent girl with CSU and comorbid autoimmune thyroiditis with thyroid function abnormality. The multidisciplinary approach to diagnostics and management of this patient as well as Omalizumab administration let us achieve total disease control and, finally, its remission.
About the Authors
Vera G. Kalugina
Central Clinical Hospital of the Russian Academy of Sciences
Russian Federation
Moscow
Russian Federation
Moscow
Leyla S. Namazova-Baranova
Central Clinical Hospital of the Russian Academy of Sciences
Russian Federation
Moscow
Russian Federation
Moscow
Elena A. Vishnyova
Central Clinical Hospital of the Russian Academy of Sciences
Russian Federation
Moscow
Russian Federation
Moscow
Anna A. Alexeyeva
Central Clinical Hospital of the Russian Academy of Sciences
Russian Federation
Moscow
Russian Federation
Moscow
Yliya Levina
Central Clinical Hospital of the Russian Academy of Sciences
Russian Federation
Moscow
Russian Federation
Moscow
Polina S. Arimova
Central Clinical Hospital of the Russian Academy of Sciences
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Pite H, Wedi B, Borrego LM, et al. Management of childhood urticaria: current knowledge and practical recommendations. Acta Derm Venereol. 2013;93(5):500–508. doi: 10.2340/000155551573.
2. Poddighe D, De Amici M, Marseglia GL. Spontaneous (autoimmune) chronic urticaria in children: current evidences, diagnostic pitfalls and therapeutic management. Recent Pat Inflamm Allergy Drug Discov. 2016;10(1):34–39. doi: 10.2174/1872213X10666 160219163502.
3. Kolkhir P, Borzova E, Grattan C, et al. Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review. Autoimmun Rev. 2017;16(12):1196–1208. doi: 10.1016/j.autrev.2017.10.003.
4. Du Toit G, Prescott R, Lawrence P, et al. Autoantibodies to the high-affinity IgE receptor in children with chronic urticaria. Ann Allergy Asthma Immunol. 2006;96(2):341–344. doi: 10.1016/S1081-1206(10)61245-8.
5. Moolani Y, Lynde C, Sussman G. Advances in understanding and managing chronic urticaria. F1000Res. 2016;5. doi: 10.12688/f1000research.7246.1.
6. Ruggeri RM, Trimarchi F, Giuffrida G, et al. Autoimmune comorbidities in Hashimoto’s thyroiditis: different patterns of association in adulthood and childhood/adolescence. Eur J Endocrinol. 2017;176:133–141.
7. McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42(2):252–265. doi: 10.1007/s12020-012-9703-2.
8. Rottem M. Chronic urticarial and autoimmune thyroid disease: is there a link? Autoimmun Rev. 2003;2(2):69–72. doi: 10.1016/s1568-9972(02)00141-6.
9. Maurer M, Altrichter S, Bieber T, Biedermann T, Brautigam M, Seyfried S, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202–209. doi:10.1016/j.jaci.2011.04.038.
10. Altrichter S. et al. IgE mediated autoallergy against thyroid peroxidase — a novel pathomechanism of chronic spontaneous urticaria? //PloS one. — 2011. — Т. 6. — №4. — С. e14794.
11. Cugno M. et al. Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria //Allergy. — 2018. — Т. 73. — №. 12. — С. 2408–2411.
12. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update. Allergy. 2018. doi: 10.1111/all.13397.
13. Klinicheskie rekomendatsii “Krapivnitsa u detei” [Internet]. Moscow: Soyuz pediatrov Rossii; Rossiyskaya assotsiatsiya allergologov i klinicheskikh immunologov; 2018. (In Russ). Available from: https://legalacts. ru/doc/klinicheskie-rekomendatsii-krapivnitsa-u-detei-utvminzdravom-rossii/. Access date: 12.06.2019.
14. Federal’nyye klinicheskie rekomendatsii “Krapivnitsa” [Internet]. Moscow: Rossiyskaya assotsiatsiya allergologov i klinicheskikh immunologov; 2018. (In Russ). Available from: http://www.nrcii.ru/specialistam/klinrecommend/urticaria.pdf. Access date: 12.06.2019.
15. Order № 433n Ministry Of Health Russia “Ob utverzhdenii polozheniya ob organizatsii klinicheskoj aprobatsii metodov profilaktiki, diagnostiki, lecheniya i reabilitatsii i okazaniya meditsinskoj pomoshchi”; dated 2015 July 10. (In Russ). Available from: https://rulaws.ru/acts/Prikaz-Minzdrava-Rossii-ot10.07.2015-N-433n/. Access date: 12.06.2019.
16. Mathias SD, Crosby RD, Zazzali JL, et al. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012;108(1):20–24. doi: 10.1016/j.anai.2011.09.008.
17. Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210– 1216. doi: 10.1016/j.jaci.2009.09.021.
18. Namazova-Baranova LS, Vishneva EA, Dobrynina EA, et al. Primary results of long-term dynamic monitoring of children with bronchial asthma of uncontrolled severe persistent course. Pediatric pharmacology. 2016;13(6):554–559. (In Russ). doi: 10.15690/pf.v13i6.1668.
19. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–935. doi: 10.1056/NEJMoa1215372.
20. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67–75. doi: 10.1038/jid.2014.306.
21. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101– 109. doi: 10.1016/j.jaci.2013.05.01
22. Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016; 137(2):474–481. doi: 10.1016/j.jaci.2015.08.023.
23. Netchiporouk E, Nguyen CH, Thuraisingham T, et al. Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series. Pediatr Allergy Immunol. 2015;26(6):585– 588. doi: 10.1111/pai.12407.
24. Comberiati P, Costagliola G, Carli N, et al. Refractory chronic spontaneous urticaria treated with omalizumab in an adolescent with common variable immunodeficiency. Front Immunol. 2019;10:1700. doi: 10.3389/fimmu.2019.01700.
25. Damiani G, Diani M, Conic RR, et al. Omalizumab in chronic urticaria: an Italian survey. Int Arch Allergy Immunol. 2019;178(1):45– 49. doi: 10.1159/000492532.
26. Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “Real-world” evidence. JAMA Dermatol. 2019;155(1):29–38. doi: 10.1001/jamadermatol.2018.3447.
27. Kalugina VG, Vishneva EA, Namazova-Baranova LS, Grinchik PR. Results of therapy including omalizumab in adolescents with recurrent urticaria: retrospective cohort study. Pediatric pharmacology. 2019;16(3):165–170. (In Russ). doi: 10.15690/pf.v16i3.2029.
Review
For citations:
Kalugina V.G., Namazova-Baranova L.S., Vishnyova E.A., Alexeyeva A.A., Levina Y., Arimova P.S. Successful Treatment of Chronic Spontaneous Urticaria Associated with Autoimmune Thyroiditis: Clinical Case. Pediatric pharmacology. 2019;16(4):229-233. (In Russ.) https://doi.org/10.15690/pf.v16i4.2052
Views:
7321
Email this article 